ERBB2 and cancer: In the invasive cancer group, statin use was associated with a reduced risk of recurrence in the ER positive cancers (HR 0.57, 95%CI 0.43-0.76, p<0.001), and this is observed in both ER+ HER2-invasive cancers (HR 0.59, 95%CI 0.43-0.80,p=0.001) and ER+ HER2+ invasive cancers (HR 0.46, 95%CI 0.22-0.95, p=0.037).